PMID- 31798767
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1947-6019 (Print)
IS  - 1947-6027 (Electronic)
IS  - 1947-6019 (Linking)
VI  - 10
IP  - 5-6
DP  - 2019
TI  - Genomic alterations of Tenascin C in highly aggressive prostate cancer: a 
      meta-analysis.
PG  - 150-159
LID - 10.18632/genesandcancer.196 [doi]
AB  - Tenascin C (TNC), an extra-cellular matrix (ECM) family gene, is expressed in 
      several cancer tissues of breast, lung, colon, and gastrointestinal tract leading 
      to proliferation, migration, invasion, angiogenesis and metastasis, but its role 
      in tumorigenesis of prostate cancer is poorly understood. We took a meta-analysis 
      approach to characterize the alterations of TNC gene in prostate cancer using 
      publicly available databases (cBioportal Version 2.2.0, 
      http://www.cBioportal.org/index.do). The analysis identified TNC alterations 
      (gene amplification) significantly in the neuroendocrine prostate cancer dataset 
      (Trento/Broad/Cornell, N = 114), which was further validated in other prostate 
      cancer datasets, including The Cancer Genome Atlas (TCGA) prostate cancer (2015). 
      In the TCGA prostate cancer dataset (N = 498), high TNC (alteration frequency, 
      36%) revealed a strong association with high diagnostic Gleason score. Genomic 
      alterations of TNC was also significantly associated (P < 0.05) with expression 
      level of genes from NOTCH, SOX and WNT family, implicating a link between TNC and 
      poorly differentiated aggressive phenotype in NEPC. TCGA prostate adenocarcinoma 
      cases with TNC alteration also demonstrated prominent decrease in disease-free 
      survival (P = 0.0637). These findings indicate a possible association of TNC to 
      the aggressive subtype of prostate cancer and warrant further functional studies 
      to evident the involvement of TNC in prostate cancer progression.
CI  - Copyright: (c) 2019 Mishra et al.
FAU - Mishra, Prachi
AU  - Mishra P
AD  - Henry Jackson Foundation for Advancement of Military Medicine, Bethesda, MD, USA.
AD  - Center for Prostate Disease Research, USU-Walter Reed Surgery, Bethesda, MD, USA.
FAU - Kiebish, Michael A
AU  - Kiebish MA
AD  - BERG LLC., Framingham, MA, USA.
FAU - Cullen, Jennifer
AU  - Cullen J
AD  - Henry Jackson Foundation for Advancement of Military Medicine, Bethesda, MD, USA.
AD  - Center for Prostate Disease Research, USU-Walter Reed Surgery, Bethesda, MD, USA.
FAU - Srinivasan, Alagarsamy
AU  - Srinivasan A
AD  - Center for Prostate Disease Research, USU-Walter Reed Surgery, Bethesda, MD, USA.
FAU - Patterson, Aliyah
AU  - Patterson A
AD  - Division of Science and Mathematics, University of the District of Columbia, 
      Washington DC, USA.
FAU - Sarangarajan, Rangaprasad
AU  - Sarangarajan R
AD  - BERG LLC., Framingham, MA, USA.
FAU - Narain, Niven R
AU  - Narain NR
AD  - BERG LLC., Framingham, MA, USA.
FAU - Dobi, Albert
AU  - Dobi A
AD  - Henry Jackson Foundation for Advancement of Military Medicine, Bethesda, MD, USA.
AD  - Center for Prostate Disease Research, USU-Walter Reed Surgery, Bethesda, MD, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Genes Cancer
JT  - Genes & cancer
JID - 101516546
PMC - PMC6872669
OTO - NOTNLM
OT  - TCGA
OT  - Tenascin C
OT  - biomarkers
OT  - neuroendocrine subtype
OT  - prostate cancer
COIS- CONFLICTS OF INTEREST M.A.K., R.S., and N.R.N. are current or former employees of 
      BERG LLC. and have stock options. N.R.N is co-founder of BERG, LLC. Other authors 
      have no conflict of interest to disclose.
EDAT- 2019/12/05 06:00
MHDA- 2019/12/05 06:01
PMCR- 2019/01/01
CRDT- 2019/12/05 06:00
PHST- 2019/12/05 06:00 [entrez]
PHST- 2019/12/05 06:00 [pubmed]
PHST- 2019/12/05 06:01 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 196 [pii]
AID - 10.18632/genesandcancer.196 [doi]
PST - ppublish
SO  - Genes Cancer. 2019;10(5-6):150-159. doi: 10.18632/genesandcancer.196.